English

Notice of Extra General Meeting of Genovis AB (publ)

Report this content

 

Shareholders of GENOVIS AB (publ) are hereby summoned to an extra General Meeting (“the Meeting”) to be held on March 28, 2011, at 5:00 p.m. at Scheelevägen 22, Lund, Sweden.

Participation

To be entitled to participate in the business of the Meeting, shareholders must be recorded in the register of shareholders maintained by Euroclear Sweden AB (former VPC AB, the Swedish Securities Register Center) on Mach 22, 2011, and must notify Genovis of their intention to attend the Meeting no later than Mach 22, 2011.

Nominee-registered shares

Shareholders whose shares are registered in the name of a nominee through the trust department of a bank or similar institution must, in order to be entitled to participate in the Meeting, request that their shares are temporarily re-registered in their own names in the register of shareholders maintained by Euroclear Sweden AB. Such registration must be effected, September 2, 2009. Shareholders are requested to inform their nominees well in advance of this date.

Notification

  • mail to GENOVIS AB (publ), Box 270, 220 07 Lund
  • telephone +46 (0)46-10 12 30/38
  • fax +46 (0)46-12 80 20
  • e-mail: info@genovis.com

When registering, shareholders should state their:

  • name/company name
  • personal identification or corporate identity number
  • address, telephone number
  • name and personal identification number of any representatives
  • name of the attendance of any assistants

Agenda

1. Opening of the meeting.

2. Election of chairman for the meeting.

3 Preparation and approval of voting list. 

4. Approval of the agenda.

5. Election of two persons to attest to the accuracy of the minutes.

6. Decision on whether proper notice of the Meeting has been made.

7. The Board of Director's proposal for resolutions regarding a new share issue.

The board proposes that the EGM resolve on a new share issue giving preferential rights to existing shareholders so that four (4) existing share entitle to subscription of three (3) new shares at a subscription price of SEK 0.65. As a result of this resolution, share capital could increase by a maximum of SEK 12,336,562.8 through the issuance of 30,841,407 shares. Furthermore, the Board proposes an oversubscription option of 13,000,000 shares, which the Board of Directors will decide on in the event that the offering is oversubscribed.

Following the completed share issue, share capital will amount to a maximum of SEK 28,785,313.6 and the number of shares to 71,963,284. The Company will raise about SEK 20 million before issue expenses. The issue will have a dilutive effect of 43%. If the oversubscription option is exercised the share capital will amount to a maximum of SEK 33,985,313.6 and the number of shares to 84,963,284. The Company will raise approximately SEK 8 million.

Record date for participation in the new issue is April 7, 2011.

8. It may be necessary to authorize the Chief Executive Officer to make minor adjustments to the resolution in accordance with point 7 in conjunction with registration and implementation thereof.

9. Conclusion of the Meeting

 

Documents

The Board of Directors' complete proposals will be made available at Genovis and on Genovis website, www.genovis.com, no later than March 14, 2011 and will be sent to shareholders that request the Company to do so. 

Lund March, 2011

Board of Directors, Genovis AB

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission (+46 (0)31 745 50 00) is the Company’s certified adviser.

Subscribe

Documents & Links